|
Getting your Trinity Audio player ready...
|
Fidson Healthcare Plc reported a 132 percent rise in profit after tax to N7.97 billion for the nine months ended September 2025, compared with N3.44 billion in the same period of 2024, driven by higher revenue and improved operating efficiency despite mounting finance costs.
Revenue grew by 56 percent to N93.08 billion from N59.73 billion a year earlier, supported by stronger product demand and price adjustments across its pharmaceutical and healthcare portfolio. Cost of sales also increased by 56 percent to N54.87 billion, resulting in a 55 percent rise in gross profit to N38.21 billion.
Operating profit nearly doubled to N16.95 billion from N8.81 billion, reflecting disciplined cost control in a period of sustained inflation and currency volatility. Administrative expenses stood at N9.91 billion, up from N5.21 billion, while selling and distribution costs rose to N7.66 billion from N5.43 billion.
Finance costs climbed 39 percent to N5.14 billion, reflecting elevated interest rates and the impact of the naira’s continued depreciation on foreign-currency borrowings. Profit before tax advanced to N11.90 billion, up from N5.14 billion, while income tax expense rose to N3.93 billion from N1.69 billion.
Read also: Nigeria leads Africa’s push for industrial growth at G20
The company’s total assets expanded to N87.00 billion as of September 2025, from N73.49 billion in December 2024, supported by increased investment in plant and equipment. Cash and bank balances improved to N7.83 billion from N4.93 billion, indicating stronger liquidity after a period of negative cash flow the previous year.
Retained earnings rose to N23.42 billion from N17.74 billion, while shareholders’ equity climbed to N29.41 billion from N23.73 billion, reflecting the company’s improved profitability and balance-sheet strength.
The nine-month performance underscores the resilience of Fidson’s operations amid Nigeria’s challenging macroeconomic environment, characterised by double-digit inflation, high energy costs, and tight monetary policy. The pharmaceutical manufacturer maintained steady output despite pressure from rising input costs and exchange-rate losses that have weighed on most manufacturers.
Fidson, one of Nigeria’s leading integrated pharmaceutical companies, continues to expand its production capacity to meet rising domestic demand and reduce dependence on imports. Its ongoing investments in technology and energy efficiency are expected to support margins in the final quarter of 2025 as the company positions for a stronger full-year performance.
